2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: University Hospital and University of Basel

Poster-Disease-modifying Therapy

October 25, 2021

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...

Read More →

Platform-Disease Modifying Therapies

October 25, 2021

Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design

Background: Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of adults with relapsing multiple...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC